MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
Bioventus Interest Expense 2011-2026 | BVS
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Bioventus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.45 M | 1.64 M | 1.29 M | -9.77 M | -1.46 M | 4.43 M | 75 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.43 M | -9.77 M | -750 K |
Quarterly Interest Expense Bioventus
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 427 K | -79 K | -561 K | -777 K | 626 K | -159 K | -63 K | -494 K | -513 K | 1.59 M | - | -115 K | -604 K | 363 K | - | -757 K | -1.64 M | -419 K | - | 3.28 M | 1.34 M | -2.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.28 M | -2.46 M | -53.9 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 203.06 | -0.38 % | $ 22.5 B | USA |
 |
Celcuity
CELC
|
5.33 M | $ 88.55 | -1.05 % | $ 4.14 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.29 | -8.72 % | $ 5.71 M | USA |
 |
Fulgent Genetics
FLGT
|
153 K | $ 18.68 | -0.53 % | $ 575 M | USA |
 |
Castle Biosciences
CSTL
|
144 K | $ 20.7 | -1.48 % | $ 600 M | USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-595 K | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 146.18 | -2.49 % | $ 11.5 B |  Irlanda |
 |
Guardant Health
GH
|
-10.5 M | $ 131.62 | 0.55 % | $ 16.5 B | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 22.97 | -2.92 % | $ 1.22 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.6 | -3.03 % | $ 7.08 M | USA |
 |
Illumina
ILMN
|
340 M | $ 160.97 | -3.15 % | $ 25 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
National Research Corporation
NRC
|
-95 K | $ 18.79 | - | $ 421 M | USA |
 |
Natera
NTRA
|
4.07 M | $ 212.07 | -3.27 % | $ 29 B | USA |
 |
Genetic Technologies Limited
GENE
|
17.6 K | - | - | $ 7.1 B |  Australia |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.31 | -2.96 % | $ 393 M | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 104.52 | 0.19 % | $ 7.05 B | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 187.51 | -0.29 % | $ 9.29 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 467.34 | -1.63 % | $ 13.5 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 131.49 | -0.86 % | $ 23.3 B |  Schweiz |
 |
NeoGenomics
NEO
|
296 K | $ 11.15 | -2.79 % | $ 1.43 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.33 | -6.48 % | $ 401 M | USA |
 |
Personalis
PSNL
|
205 K | $ 9.59 | 1.8 % | $ 856 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.46 | 1.34 % | $ 25.1 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 76.17 | 2.86 % | $ 4.56 B | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 7.18 | -2.05 % | $ 300 M | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.58 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.05 | -1.91 % | $ 4.71 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 266.16 | 0.34 % | $ 22.1 B | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 469.34 | -1.33 % | $ 177 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.65 | -3.7 % | $ 233 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.1 | -1.57 % | $ 1.97 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |